Dr. Prince assumed the role of CEO in January 2026. He joined Neovii from Roche Oncology, where he served as Head of Strategy and Acting Chief of Staff for the Research and Early Development (pRED) organization. Previously, he held senior management positions at bluebird bio and Novartis Oncology. Dr. Prince brings extensive industry experience to Neovii, with expertise in both R&D and commercial functions. He holds a PhD in Molecular Genetics and a Master’s degree in Cell Biology, both from the University of Basel, Switzerland.

With more than 20 years of experience in the pharmaceutical industry, Mr. Doucette joined the company in 2018. Previously, he held senior international finance and commercial positions in Wyeth Pharmaceuticals, later acquired by Pfizer Inc. His most recent role was Regional Commercial Director SEE/Turkey/Greece/Israel for Pfizer’s Consumer Healthcare business unit. Mr. Doucette holds a degree in business administration from Vienna University of Economics and Business.

Mr. Hofmann joined Neovii in 2014 where he served as a Head of Production until he has taken over the responsibility as a Managing Director for Neovii Biotech GmbH. He is bringing over 15 years of experience in the development and manufacturing of biological products. Prior to joining Neovii, he held senior leadership positions at Boehringer-Ingelheim, Fresenius Biotech and Sandoz. Mr. Hofmann holds a biotechnology engineer degree from the University of Anhalt, Germany.